Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
29. April 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., April 29, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
28. April 2022 01:00 ET
|
Cara Therapeutics, Inc.
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patientsFirst launches in Europe expected in H2 2022 ST. GALLEN, Switzerland...
Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
05. April 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022
04. April 2022 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., April 04, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus
28. März 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., March 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting
08. März 2022 16:01 ET
|
Cara Therapeutics, Inc.
Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients Oral...
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
01. März 2022 16:01 ET
|
Cara Therapeutics, Inc.
KORSUVA™ (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed Initiation of Oral KORSUVA (difelikefalin) Phase 3 pruritus...
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
25. Februar 2022 07:15 ET
|
Cara Therapeutics, Inc.
Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefalin) as first therapy in Europe for the treatment of chronic kidney disease associated-pruritus...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
22. Februar 2022 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
Cara Therapeutics to Host Virtual R&D Day on March 11, 2022
18. Februar 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...